Physician profile
Isak Isakov
NPI 1770521775
$474,396.67
in general payments reported to CMS, 2019-2025
22 companies · $64K in 2025
The $64K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $41K · 2021: $60K · 2022: $73K · 2023: $68K · 2024: $71K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Consulting Fee: $23K · Honoraria: $18K · Food and Beverage: $14K · Travel and Lodging: $8,979 · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138,054.78 |
| Consulting Fee | $23,479.00 |
| Honoraria | $17,551.00 |
| Food and Beverage | $13,856.06 |
| Travel and Lodging | $8,978.69 |
| Education | $393.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $140,837.81 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $101,746.60 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $74,674.81 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48,180.39 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $33,937.33 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $21,619.76 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $13,807.23 | 2021-2025 | |
| Indivior INC. | $13,184.55 | 2019-2024 | Perseris, Sublocade |
| Janssen Pharmaceuticals, INC | $11,404.48 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| E.R. Squibb & Sons, L.L.C. | $9,288.77 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $2,482.47 | 2019-2025 | Trintellix |
| Lundbeck LLC | $1,196.89 | 2019-2025 | Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $783.36 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $725.54 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $117.66 | 2020 | |
| Avanir Pharmaceuticals, INC. | $47.95 | 2019 | |
| Braeburn INC. | $45.24 | 2024-2025 | Brixadi |
| Noven Therapeutics, LLC | $40.41 | 2021 | |
| Acadia Pharmaceuticals INC | $36.57 | 2022 | |
| Ironshore Pharmaceuticals INC. | $22.76 | 2023 | Jornay Pm |
| Validus Pharmaceuticals LLC | $16.09 | 2025 | Raldesy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isak Isakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.